150767-02-5

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
Tert-butyl N-[(4-Methoxyphenyl)MethylaMino]carbaMate is used as a building block in the synthesis of new drugs for its potential medicinal properties. Its unique structure allows it to be a key component in the development of pharmaceuticals targeting the central nervous system.
Used in the Synthesis of CNS-targeting Drugs:
In the pharmaceutical industry, Tert-butyl N-[(4-Methoxyphenyl)MethylaMino]carbaMate is used as a precursor in the creation of drugs that aim to treat conditions related to the central nervous system. Its specific chemical properties make it suitable for this application, contributing to the advancement of treatments for neurological disorders and diseases.

Upstream product

• 123-11-5 4-methoxy-benzaldehyde 
• 402723-13-1 p-(methoxyphenyl)-carbaldehyde tert-butoxycarbonylhydrazone 
• 870-46-2 t-butoxycarbonylhydrazine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 150767-00-3 N-t-butoxycarbonyl-N'-4-methoxybenzaldehyde hydrazone 

Downstream Products

• 161852-56-8 N'-((2S,3S)-3-tert-Butoxycarbonylamino-2-hydroxy-4-phenyl-butyl)-N'-(4-methoxy-benzyl)-hydrazinecarboxylic acid tert-butyl ester 
• 949556-61-0 1-(4-methoxybenzyl)-3-methyl-1H-pyrazol-5-amine 
• 1434003-97-0 tert-butyl 5-[2-azido-4-(ethoxycarbonyl)phenyl]-2-benzyl-3-isopropyl-2,3-dihydro-1H-pyrazole-1-carboxylate 
• 1372807-97-0 (S)-2-(4-methoxybenzyl)-4-(4-nitrobenzyl)-5-isobutyl-1,2,4-triazine-3,6-dione 
• 1372807-64-1 C₂₈H₃₈N₄O₈ 
• 1372807-96-9 (S)-2-(4-methoxybenzyl)-4-benzyl-5-isobutyl-[1,2,4]-triazine-3,6-dione 
• 1372807-63-0 C₂₈H₃₉N₃O₆ 
• 1372807-78-7 C₂₀H₂₉N₃O₆ 
• 412327-07-2 [(4-methoxyphenyl)methyl] hydrazine dihydrochloride 
• 161852-00-2 N'-((2S,3S)-3-{(S)-3-Carbamoyl-2-[(quinoline-2-carbonyl)-amino]-propionylamino}-2-hydroxy-4-phenyl-butyl)-N'-(4-methoxy-benzyl)-hydrazinecarboxylic acid tert-butyl ester 
• 161852-71-7 (S)-N¹-{(1S,2S)-1-Benzyl-2-hydroxy-3-[N-(4-methoxy-benzyl)-hydrazino]-propyl}-2-[(quinoline-2-carbonyl)-amino]-succinamide 
• 161852-68-2 N'-((2S,3S)-3-Amino-2-hydroxy-4-phenyl-butyl)-N'-(4-methoxy-benzyl)-hydrazinecarboxylic acid tert-butyl ester 
• 161852-67-1 N'-[(2S,3S)-2-Hydroxy-4-phenyl-3-(2,2,2-trifluoro-acetylamino)-butyl]-N'-(4-methoxy-benzyl)-hydrazinecarboxylic acid tert-butyl ester 
• 150767-07-0 N'-((2S,3S)-3-Benzyloxycarbonylamino-2-hydroxy-4-phenyl-butyl)-N'-(4-methoxy-benzyl)-hydrazinecarboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

Exploration of a Au(i)-mediated three-component reaction for the synthesis of DNA-tagged highly substituted spiroheterocycles

We demonstrate a Au(i)-mediated three-component reaction to DNA-tagged highly substituted 6-oxa-1,2-diazaspiro[4.4]nonanes from either DNA-coupled aldehydes, hydrazides, or alkynols. The choice of the starting material coupled to the DNA tag was critial for the purity of the product as the DNA-aldehyde conjugate yielded the purest products, whereas the alkynol- and hydrazide conjugates returned complex product mixtures. The reaction was compatible with thymine-, cytosine-, and, surprisingly, with adenine-DNA, while guanine-containing DNA strands were degraded under the reaction conditions.

Gold-catalyzed three-component spirocyclization: A one-pot approach to functionalized pyrazolidines

An efficient, highly atom economic synthesis of hitherto unknown spirocyclic pyrazolidines in a one-pot process was developed. The gold-catalyzed three-component coupling of alkynols, hydrazines and aldehydes or ketones likely proceeds via cycloisomerization of the alkynol to an exocyclic enol ether and subsequent [3 + 2]-cycloaddition of an azomethine ylide. A library of 29 derivatives with a wide range of functional groups was synthesized in up to 97% yield. With this new method, every position in the final product can be substituted which renders the method ideal for applications in combinatorial or medicinal chemistry.

Synthesis and biological evaluation of Hydrazone derivatives as antifungal agents

Emerging yeasts are among the most prevalent causes of systemic infections with high mortality rates and there is an urgent need to develop specific, effective and non-Toxic antifungal agents to respond to this issue. In this study 35 aldehydes, hydrazones and hydrazines were obtained and their antifungal activity was evaluated against Candida species (C. parapsilosis, C.Tropicalis, C. krusei, C. albicans, C. glabrata and C. lusitaneae) and Trichosporon asahii, in an in vitro screening. The minimum inhibitory concentrations (MICs) of the active compounds in the screening was determined against 10 clinical isolates of C. parapsilosis and 10 of T. asahii. The compounds 4-pyridin-2-ylbenzaldehyde] (13a) and tert-butyl-(2Z)-2-(3,4,5-Trihydroxybenzylidine)hydrazine carboxylate (7b) showed the most promising MIC values in the range of 16-32 μg/mL and 8-16 μg/mL, respectively. The compounds' action on the stability of the cell membrane and cell wall was evaluated, which suggested the action of the compounds on the fungal cell membrane. Cell viability of leukocytes and an alkaline comet assay were performed to evaluate the cytotoxicity. Compound 13a was not cytotoxic at the active concentrations. These results support the discovery of promising candidates for the development of new antifungal agents.

Development and a practical synthesis of the JAK2 inhibitor LY2784544

The route selection and process research and development of a practical synthesis for JAK2 inhibitor LY2784544 is described. The first-generation synthesis route, similar to that used in discovery for derivatization of a benzylic amine moiety, was 14 overall steps and possessed several steps that required extensive development for large-scale production. Route selection considerations led to a modified synthesis that utilized a novel vanadium-catalyzed carbon-carbon bond-forming arylation reaction for incorporation of the key benzylic morpholine moiety. A protecting group used to mask an amino pyrazole unit was modified from PMB to tert-butyl, resulting in a dramatic reduction in the overall length of the route. These two major changes resulted in an eight-step synthesis, which was six steps shorter than the first-generation synthesis. In the pilot plant, the new synthesis was scaled to produce >100 kg of LY2784544 in high yield and purity under GMP conditions. The overall development including the vanadium-catalyzed C-C bond-forming methodology, a ketone reductive deoxygenation, and a palladium-catalyzed amination is described.

Combinatorial aid for underprivileged scaffolds: Solution and solid-phase strategies for a rapid and efficient access to novel aza-diketopiperazines (aza-DKP)

An efficient solution-phase synthesis of aza-diketopiperazines (aza-DKP, triazinediones) is reported. A structurally diverse collection of c-[aza-alkylGly-Pro] derivatives and yet unreported 2,4,5-trisubstituted-1,2,4- triazine-3,6-diones has been synthesized starting from Fmoc-l-Pro-OH and various Fmoc-l-amino acids. To extend the practical value of this class of dipeptidomimetics, a general solid-phase synthesis approach amenable to library production was developed on both Wang-PS and HMBA-PS resins. The final acidic treatment of the resins in TFA/water mixture at room temperature enabled the rapid and quantitative cyclization/release highly pure triazinediones. The conformational preferences and the spatial organization of the three substituents of a representative 2,4,5-trisubstituted-1,2,4-triazine-3,6-dione were investigated by X-ray diffraction and 1H NMR spectroscopy.

AMINO PYRAZOLE COMPOUND

The present invention provides amino pyrazole compounds useful in the treatment of chronic myeloproliferative disorders and various cancers, e.g., glioblastoma, breast cancer, multiple myeloma, prostate cancer, and leukemias.

The efficient synthesis of azaamino acids

An efficient method of synthesis of N-t-butoxycarbonyl-azaamino acid ethyl esters has been described. This method consisted of three stages including: hydrazone formation, its reduction and acylation with ethyl chloroformate. The second step - reduction of the hydrazones to the appropriate hydrazides - was the most challenging. Some reducing agents have been tested, though NaBH3CN was found to lead to the final products with the highest yields in relatively short time and even to allow the selective reduction of C-N bond in the presence of nitro group.

Antiretroviral hydrazine derivatives

The invention relates to compounds of formula STR1 and salts, pharmaceutical compositions, intermediates and processes of preparation thereof.

Aza-peptide analogs as potent human immunodeficiency virus type-1 protease inhibitors with oral bioavailability

A series of aza-peptide analogs with a (hydroxyethyl)hydrazine isostere has been synthesized as HIV-1 protease inhibitors using a simple synthetic scheme. Structure-activity studies based on the X-ray of a previously described inhibitor-enzyme complex led to potent inhibitors with antiviral activity in the low-nanomolar range. The S-configuration of the transition- state hydroxyl group was preferred in this series. Small modifications of the P2P3 and P2'P3' substituents had little effect on enzyme inhibition but greatly influenced the pharmacokinetic profile. As a result of these studies, the symmetrically acylated compound 8a and its close analog 24a bearing a methyl carbamate in P3 and an ethyl carbamate in P3' position were identified as potent inhibitors with plasma concentrations exceeding antiviral ED50 values 150-fold following oral application in mice.

Facile Synthesis of Potent HIV-1 Protease Inhibitors containing a Novel Pseudo-symmetric Dipeptide Isostere

A series of potent inhibitors of the HIV-1 protease containing a novel pseudo-symmetric dipeptide isostere 3 was synthesized via ring opening of a protected epoxide with various substituted hydrazines.